These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
6. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770 [TBL] [Abstract][Full Text] [Related]
7. Adult IDH wild-type lower-grade gliomas should be further stratified. Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485 [TBL] [Abstract][Full Text] [Related]
8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
9. Correlation of immune phenotype with IDH mutation in diffuse glioma. Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337 [TBL] [Abstract][Full Text] [Related]
10. A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets. Nguyen HD; Allaire A; Diamandis P; Bisaillon M; Scott MS; Richer M BMC Med; 2020 Oct; 18(1):280. PubMed ID: 33059718 [TBL] [Abstract][Full Text] [Related]
11. Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomas-A Single-Institution, Nine-Year Data. Lasica AB; Jaunmuktane Z; Fersht N; Kirkman MA; Dixon L; Hoskote C; Brandner S; Samandouras G World Neurosurg; 2021 Jul; 151():e217-e233. PubMed ID: 33866029 [TBL] [Abstract][Full Text] [Related]
12. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258 [TBL] [Abstract][Full Text] [Related]
13. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Berzero G; Di Stefano AL; Ronchi S; Bielle F; Villa C; Guillerm E; Capelle L; Mathon B; Laurenge A; Giry M; Schmitt Y; Marie Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M Neuro Oncol; 2021 Jun; 23(6):955-966. PubMed ID: 33173941 [TBL] [Abstract][Full Text] [Related]
14. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
15. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? Weller M; Reifenberger G Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376 [TBL] [Abstract][Full Text] [Related]
16. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266 [TBL] [Abstract][Full Text] [Related]
17. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924 [TBL] [Abstract][Full Text] [Related]
18. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review. Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563 [TBL] [Abstract][Full Text] [Related]
19. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis. Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]